[A23-77] Eftrenonacog alfa (haemophilia B) – Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2023
Project no.:
A23-77
Commission:
Commission awarded on 01.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Treatment and prophylaxis of bleeding in patients of all age groups with haemophilia B (congenital factor IX deficiency)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-77
| Project no. | Title | Status |
|---|---|---|
| G16-06 | Eftrenonacog alfa - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |